IL319205A - תצמידי נוגדן כנגדtissue factor ותרופה ושימושיהם - Google Patents
תצמידי נוגדן כנגדtissue factor ותרופה ושימושיהםInfo
- Publication number
- IL319205A IL319205A IL319205A IL31920525A IL319205A IL 319205 A IL319205 A IL 319205A IL 319205 A IL319205 A IL 319205A IL 31920525 A IL31920525 A IL 31920525A IL 319205 A IL319205 A IL 319205A
- Authority
- IL
- Israel
- Prior art keywords
- tissue factor
- drug conjugates
- factor antibody
- antibody
- conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263404447P | 2022-09-07 | 2022-09-07 | |
| US202363498233P | 2023-04-25 | 2023-04-25 | |
| PCT/US2023/073516 WO2024054821A2 (en) | 2022-09-07 | 2023-09-06 | Tissue factor antibody-drug conjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319205A true IL319205A (he) | 2025-04-01 |
Family
ID=90191921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319205A IL319205A (he) | 2022-09-07 | 2023-09-06 | תצמידי נוגדן כנגדtissue factor ותרופה ושימושיהם |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP4583922A2 (he) |
| JP (1) | JP2025530129A (he) |
| KR (1) | KR20250060248A (he) |
| CN (1) | CN120129535A (he) |
| AU (1) | AU2023338206A1 (he) |
| CA (1) | CA3265517A1 (he) |
| CL (1) | CL2025000595A1 (he) |
| CO (1) | CO2025003047A2 (he) |
| CR (1) | CR20250074A (he) |
| DO (1) | DOP2025000050A (he) |
| IL (1) | IL319205A (he) |
| MX (1) | MX2025002614A (he) |
| PE (1) | PE20251256A1 (he) |
| TW (1) | TW202423991A (he) |
| WO (1) | WO2024054821A2 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025081117A2 (en) * | 2023-10-13 | 2025-04-17 | Sutro Biopharma, Inc. | Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220153871A1 (en) * | 2018-01-04 | 2022-05-19 | Iconic Therapeutics, Inc. | Anti-Tissue Factor Antibodies, Antibody-Drug Conjugates, and Related Methods |
| CA3198788A1 (en) * | 2021-01-15 | 2022-07-21 | R.P. Scherer Technologies, Llc | Camptothecine antibody-drug conjugates and methods of use thereof |
| JP2025516569A (ja) * | 2022-05-13 | 2025-05-30 | エグゼリクシス， インコーポレイテッド | ５ｔ４抗体薬物複合体及びその使用 |
-
2023
- 2023-09-06 TW TW112133938A patent/TW202423991A/zh unknown
- 2023-09-06 PE PE2025000509A patent/PE20251256A1/es unknown
- 2023-09-06 IL IL319205A patent/IL319205A/he unknown
- 2023-09-06 CR CR20250074A patent/CR20250074A/es unknown
- 2023-09-06 AU AU2023338206A patent/AU2023338206A1/en active Pending
- 2023-09-06 WO PCT/US2023/073516 patent/WO2024054821A2/en not_active Ceased
- 2023-09-06 EP EP23863945.4A patent/EP4583922A2/en active Pending
- 2023-09-06 KR KR1020257010473A patent/KR20250060248A/ko active Pending
- 2023-09-06 JP JP2025513408A patent/JP2025530129A/ja active Pending
- 2023-09-06 CA CA3265517A patent/CA3265517A1/en active Pending
- 2023-09-06 CN CN202380076310.9A patent/CN120129535A/zh active Pending
-
2025
- 2025-03-04 CL CL2025000595A patent/CL2025000595A1/es unknown
- 2025-03-04 MX MX2025002614A patent/MX2025002614A/es unknown
- 2025-03-05 DO DO2025000050A patent/DOP2025000050A/es unknown
- 2025-03-10 CO CONC2025/0003047A patent/CO2025003047A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN120129535A (zh) | 2025-06-10 |
| CR20250074A (es) | 2025-04-10 |
| WO2024054821A2 (en) | 2024-03-14 |
| JP2025530129A (ja) | 2025-09-11 |
| KR20250060248A (ko) | 2025-05-07 |
| CO2025003047A2 (es) | 2025-03-27 |
| CL2025000595A1 (es) | 2025-05-02 |
| TW202423991A (zh) | 2024-06-16 |
| CA3265517A1 (en) | 2024-03-14 |
| WO2024054821A3 (en) | 2024-04-11 |
| AU2023338206A1 (en) | 2025-03-06 |
| PE20251256A1 (es) | 2025-05-06 |
| MX2025002614A (es) | 2025-04-02 |
| EP4583922A2 (en) | 2025-07-16 |
| DOP2025000050A (es) | 2025-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL308246A (he) | נגזרות אקזאטקאן וצימודים של נוגדנים עם תרופות מהן | |
| CA3256212A1 (en) | ANTIBODY-DRUG CONJUGATES, PREPARATION PROCESSES AND ASSOCIATED USES | |
| IL304168A (he) | מצומדי נוגדן-תרופה מייעדים b7h4 ושיטות לשימוש בהם | |
| IL302122A (he) | צימוד נוגדן–תרופות ויישום שלו | |
| IL314828A (he) | צימודים של נוגדנים-תרופות ושימושיהם | |
| AU2022205057A9 (en) | B7h4-targeted antibody-drug conjugates and methods of use thereof | |
| AU2021359562A9 (en) | Antibody-drug conjugate and application thereof | |
| IL317101A (he) | תצמידי נוגדן-תרופה של תרכובות אנטי-סרטניות ושיטות לשימוש בהם | |
| IL320634A (he) | נגזרות exatecan וצימודים של נוגדנים תרופות | |
| IL299334A (he) | תצמידי נוגדן-תרופה נגד-גורם רקמה והשימוש בהם בטיפול בסרטן | |
| IL299184A (he) | תרופות נוגדות חומצה פולית ונוגדנים-תרופות מצומדות | |
| IL300176A (he) | נוגדנים אנטי- cd228ותצמידי נוגדן-תרופה | |
| IL307282A (he) | תצמידי תרופת נגדן נגד her2 ושמימושים בהם | |
| IL318188A (he) | מצומדי נוגדן-תרופה | |
| IL319484A (he) | תכשירים נוגדנים לתרופות המכוונים ל-napi2b ושיטות שימוש | |
| IL320894A (he) | תצמידי נוגדן ceacam5 – תרופה ושיטות לשימוש בהם | |
| IL324678A (he) | קושרי תרופות ותצמידי תרופות | |
| IL316790A (he) | תצמידי נוגדן כנגד5t4 עם תרופה ושימושיהם | |
| IL319205A (he) | תצמידי נוגדן כנגדtissue factor ותרופה ושימושיהם | |
| IL316020A (he) | צימודים של תרופות נוגדות על בסיס ארבולין ושיטות שימוש | |
| IL324461A (he) | נוגדן-תרופה מצומד נגד-pdl1 ושימוש בו | |
| IL325400A (he) | מצומדי תרופה-נוגדן נגד cacng1 אנושי ושימושים שלהם | |
| HK40121438A (en) | Antibody-drug conjugate and use thereof | |
| CA3289393A1 (en) | Anti-cdh6 antibody-drug conjugate and use thereof | |
| CA3278529A1 (en) | Anti-bdca2 antibody-drug conjugate and use thereof |